Genzyme Corporation

Summary

Organization: Genzyme Corporation
Country: USA

Top Publications

  1. doi Antiangiogenic agents and targets: A perspective
    Beverly A Teicher
    Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701 9322, USA
    Biochem Pharmacol 81:6-12. 2011
  2. ncbi Optimized preservation of CNS morphology for the identification of glycogen in the Pompe mouse model
    Tatyana V Taksir
    Department of Pathology, Genzyme Corporation, One Mountain Road, Framingham, MA 01701 9322, USA
    J Histochem Cytochem 55:991-8. 2007
  3. ncbi Targeting dysregulated cell cycle and apoptosis for polycystic kidney disease therapy
    Oxana Ibraghimov-Beskrovnaya
    Genzyme Corporation, Framingham, Massachusetts 01701, USA
    Cell Cycle 6:776-9. 2007
  4. ncbi In vitro cystogenesis: the search for drugs antagonizing cyst development
    Oxana Ibraghimov-Beskrovnaya
    Genzyme Corporation, 5, Mountain Road, Framingham, MA 01701 9322, Etats Unis
    Nephrol Ther 2:S109-14. 2006
  5. ncbi Therapeutic success via targeted approaches and strategic partnerships with clinical laboratories
    Glenn A Miller
    Genzyme Analytical Services, 3400 Computer Drive, Westborough, MA 01581, USA
    IDrugs 10:181-4. 2007
  6. ncbi The use of chitosan as a flocculant in mammalian cell culture dramatically improves clarification throughput without adversely impacting monoclonal antibody recovery
    Frank Riske
    Purification Development, Genzyme Corporation, Framingham, MA 01701, USA
    J Biotechnol 128:813-23. 2007
  7. ncbi Review article: tolevamer, a novel toxin-binding polymer: overview of preclinical pharmacology and physicochemical properties
    R H Barker
    Pharmacology and Preclinical Development, Genzyme Drug Discovery and Development, Waltham, MA 02541, USA
    Aliment Pharmacol Ther 24:1525-34. 2006
  8. ncbi Tumor models for efficacy determination
    Beverly A Teicher
    Genzyme Corporation, 1 Mountain Road, Framingham, MA 01701, USA
    Mol Cancer Ther 5:2435-43. 2006
  9. ncbi Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model
    Sharon D Morgenbesser
    Department of Oncology Research, Genzyme Corporation, Framingham, MA 01701 9322, USA
    Prostate 67:83-106. 2007
  10. ncbi Analysis of creatinine in mouse and rat serum by ion exchange high performance liquid chromatography for in vivo studies of renal function
    Kenneth J Fountain
    Analytical Research and Development, Drug and Biomaterial Research and Development, Genzyme Corporation, 153 2nd Avenue, Waltham, MA 02451, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 846:245-51. 2007

Detail Information

Publications62

  1. doi Antiangiogenic agents and targets: A perspective
    Beverly A Teicher
    Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701 9322, USA
    Biochem Pharmacol 81:6-12. 2011
    ....
  2. ncbi Optimized preservation of CNS morphology for the identification of glycogen in the Pompe mouse model
    Tatyana V Taksir
    Department of Pathology, Genzyme Corporation, One Mountain Road, Framingham, MA 01701 9322, USA
    J Histochem Cytochem 55:991-8. 2007
    ..The modified paraffin method with periodic acid postfixation resulted in improved tissue morphology and glycogen preservation. Both techniques provide accurate anatomic evaluation of the glycogen distribution in Pompe mouse brain...
  3. ncbi Targeting dysregulated cell cycle and apoptosis for polycystic kidney disease therapy
    Oxana Ibraghimov-Beskrovnaya
    Genzyme Corporation, Framingham, Massachusetts 01701, USA
    Cell Cycle 6:776-9. 2007
    ..Thus, therapies directly targeting coordinate regulation of proliferation and apoptosis are emerging as effective approaches to treat multiple renal diseases...
  4. ncbi In vitro cystogenesis: the search for drugs antagonizing cyst development
    Oxana Ibraghimov-Beskrovnaya
    Genzyme Corporation, 5, Mountain Road, Framingham, MA 01701 9322, Etats Unis
    Nephrol Ther 2:S109-14. 2006
    ..We have used in vitro cystogenesis assay for a high throughput screen of small molecule drugs and identified drugs specifically inhibiting cystogenesis but not tubulogenesis in vitro...
  5. ncbi Therapeutic success via targeted approaches and strategic partnerships with clinical laboratories
    Glenn A Miller
    Genzyme Analytical Services, 3400 Computer Drive, Westborough, MA 01581, USA
    IDrugs 10:181-4. 2007
    ..Strategic partnerships between drug companies and clinical laboratories will be the centerpiece of this new era of medical treatment, providing higher-resolution diagnostics as well as more efficacious and safer treatment options...
  6. ncbi The use of chitosan as a flocculant in mammalian cell culture dramatically improves clarification throughput without adversely impacting monoclonal antibody recovery
    Frank Riske
    Purification Development, Genzyme Corporation, Framingham, MA 01701, USA
    J Biotechnol 128:813-23. 2007
    ..The procedure for utilizing chitosan is facile, easily implemented, and highly effective in improving material clarity and increasing material throughput...
  7. ncbi Review article: tolevamer, a novel toxin-binding polymer: overview of preclinical pharmacology and physicochemical properties
    R H Barker
    Pharmacology and Preclinical Development, Genzyme Drug Discovery and Development, Waltham, MA 02541, USA
    Aliment Pharmacol Ther 24:1525-34. 2006
    ..Tolevamer is a novel toxin-binding polymer that is currently being investigated in clinical trials for the treatment of patients who have Clostridium difficile-associated diarrhoea...
  8. ncbi Tumor models for efficacy determination
    Beverly A Teicher
    Genzyme Corporation, 1 Mountain Road, Framingham, MA 01701, USA
    Mol Cancer Ther 5:2435-43. 2006
    ..Each of these types of models has advantages and disadvantages to the "drug hunter" searching for improved treatments...
  9. ncbi Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model
    Sharon D Morgenbesser
    Department of Oncology Research, Genzyme Corporation, Framingham, MA 01701 9322, USA
    Prostate 67:83-106. 2007
    ..A major focus of prostate cancer research has been to identify genes that are deregulated during tumor progression, potentially providing diagnostic markers and therapeutic targets...
  10. ncbi Analysis of creatinine in mouse and rat serum by ion exchange high performance liquid chromatography for in vivo studies of renal function
    Kenneth J Fountain
    Analytical Research and Development, Drug and Biomaterial Research and Development, Genzyme Corporation, 153 2nd Avenue, Waltham, MA 02451, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 846:245-51. 2007
    ..The method was used for routine preclinical diagnosis of rat and mouse model renal function, and for the evaluation of renal disease treatment efficacy...
  11. ncbi Protein kinase C as a therapeutic target
    Beverly A Teicher
    Genzyme Corporation, Framingham, Massachusetts 01701 9322, USA
    Clin Cancer Res 12:5336-45. 2006
  12. ncbi Performance comparison of protein A affinity resins for the purification of monoclonal antibodies
    K Swinnen
    Technology Department, Genzyme, Cipalstraat 8, Geel, Belgium
    J Chromatogr B Analyt Technol Biomed Life Sci 848:97-107. 2007
    ..Certain evaluation parameters may be more important than others, depending on the specific situation. Therefore, a case-by-case evaluation is recommended...
  13. ncbi Cell and gene-based therapies for the lysosomal storage diseases
    Bradley L Hodges
    Genzyme Corporation, 31 New York Avenue, Framingham, MA 01701 9322, USA
    Curr Gene Ther 6:227-41. 2006
    ..Here, we review the utility of various gene therapy strategies under consideration for the treatment of the LSD, including viral and non-viral gene transfer approaches, as well as stem cell transplantation...
  14. ncbi Fibroblast growth factor 23: the making of a hormone
    S C Schiavi
    Endocrine and Renal Sciences, Genzyme Corporation, Framingham, Massachusetts, USA
    Kidney Int 69:425-7. 2006
    ..In this issue, Nagano and colleagues report that FGF23 can be modulated by intermittently high dietary phosphate in the presence of compromised renal function...
  15. ncbi Structure of pericellular matrix around agarose-embedded chondrocytes
    M A DiMicco
    Center for Biomedical Engineering and Biological Engineering Division, Massachusetts Institute of Technology, Cambridge, MA, USA
    Osteoarthritis Cartilage 15:1207-16. 2007
    ..Determine whether the structure of the type VI collagen component of the chondrocyte pericellular matrix (PCM) generated by agarose-embedded chondrocytes in culture is similar to that found in native articular cartilage...
  16. ncbi Quality control in clinical flow cytometry
    Teri A Oldaker
    Genzyme Genetics, 5300 McConnell Avenue, Los Angeles, CA 90066, USA
    Clin Lab Med 27:671-85, viii. 2007
    ..In order to obtain accurate and reproducible results, it is essential to have optimized and standardized procedures, rigorous quality control, and assurance programs encompassing preanalytic, analytic, and postanalytic processes...
  17. ncbi Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function
    Qun Zhou
    Genzyme Corporation, P O Box 9322, Framingham, Massachusetts 01701 9322, USA
    Biotechnol Bioeng 99:652-65. 2008
    ..The use of kifunensine provides a simple and rapid method for the production of antibodies with increased ADCC without the time-consuming need to re-engineer either the antibody molecule or the host cell line...
  18. ncbi Endosialin: from vascular target to biomarker for human sarcomas
    Rebecca G Bagley
    Genzyme Corporation, 49 New York Avenue, Framingham, MA 01710 9322, USA
    Biomark Med 3:589-604. 2009
    ..Thus, endosialin holds potential value both as a therapeutic target and as a biomarker for certain human cancers...
  19. doi Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models
    William M Siders
    Genzyme Corporation, Framingham, MA 010701, USA
    Leuk Lymphoma 51:1293-304. 2010
    ....
  20. doi Trends in prenatal screening and diagnostic testing among women referred for advanced maternal age
    Naomi Nakata
    Genzyme Genetics, Los Angeles, CA 90066, USA
    Prenat Diagn 30:198-206. 2010
    ....
  21. doi Use of direct fluorescence labeling and confocal microscopy to determine the biodistribution of two protein therapeutics, Cerezyme and Ceredase
    Peter A Piepenhagen
    Department of Pathology, Genzyme Corporation, Framingham, Massachusetts 01701 9322, USA
    Microsc Res Tech 73:694-703. 2010
    ..This approach provides an easy and straightforward means of assessing the tissue and cell type-specific biodistribution of multiple protein therapeutics in target organs using a minimal number of animals...
  22. doi Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy
    Beth L Thurberg
    Department of Pathology, Genzyme Corporation, Cambridge, MA, USA
    Circulation 119:2561-7. 2009
    ..These disturbances are caused by globotriaosylceramide (GL-3) accumulation in the heart resulting from lysosomal alpha-galactosidase A deficiency...
  23. doi Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents
    Leslie S Kurtzberg
    Genzyme Corporation, Framingham, MA 01701, USA
    Cancer Chemother Pharmacol 64:1029-38. 2009
    ..The bone marrow toxicity and human tumor xenograft activity of three tubulin-binding compounds, vincristine, paclitaxel, and tasidotin were compared...
  24. ncbi Human mesenchymal stem cells from bone marrow express tumor endothelial and stromal markers
    Rebecca G Bagley
    Genzyme Corporation, Framingham, MA 01701 9322, USA
    Int J Oncol 34:619-27. 2009
    ..Endosialin expression by both CAF and MSC further implies the potential contribution of MSC to tumor stroma via differentiation into tumor stromal fibroblasts...
  25. doi Human endothelial precursor cells express tumor endothelial marker 1/endosialin/CD248
    Rebecca G Bagley
    Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701 9322, USA
    Mol Cancer Ther 7:2536-46. 2008
    ..The data presented here on endothelial genes that are up-regulated in tumor vasculature and in EPC support the hypothesis that the angiogenesis process in cancer can involve EPC...
  26. doi Multiplex enzyme assay screening of dried blood spots for lysosomal storage disorders by using tandem mass spectrometry
    X Kate Zhang
    Genzyme Corporation, Framingham, MA 01701, USA
    Clin Chem 54:1725-8. 2008
    ..We modified the assay for high-throughput use in screening laboratories...
  27. doi Sevelamer restores bone volume and improves bone microarchitecture and strength in aged ovariectomized rats
    T Kuber Sampath
    Genzyme Corporation, Framingham, Massachusetts 01701, USA
    Endocrinology 149:6092-102. 2008
    ..PTH, fibroblast growth factor-23, and cytokine profile in serum were not significantly changed. Together, these results suggest that sevelamer in food increases the BV and improves biomechanical properties of bone in OVX rats...
  28. pmc Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease
    A J McVie-Wylie
    Biologics Research and Development, Genzyme Corporation, One Mountain Road, Framingham, MA 01701, USA
    Mol Genet Metab 94:448-55. 2008
    ....
  29. ncbi The systemic administration of lethal toxin achieves a growth delay of human melanoma and neuroblastoma xenografts: assessment of receptor contribution
    Cecile Rouleau
    Genzyme Corporation, Framingham, MA 01701, USA
    Int J Oncol 32:739-48. 2008
    ..The therapeutic potential of LeTx needs to be further investigated in non-melanoma tumor models expressing the ANTXR1/TEM8 and/or ANTXR2/CMG2 protein...
  30. ncbi A neocentromere derived from a supernumerary marker deleted from the long arm of chromosome 6
    N Qin
    Genzyme Genetics, Orange, CA 92868, USA
    Cytogenet Genome Res 119:154-7. 2007
    ..The child's karyotype was re-interpreted to be unbalanced due to the presence of the abnormal chromosome 6, but without the marker. The clinical phenotype associated with the interstitial deletion of chromosome 6 is also reported...
  31. ncbi Preclinical and clinical development of deferitrin, a novel, orally available iron chelator
    Joanne M Donovan
    Genzyme, Drug Discovery and Development, 153 Second Ave, Waltham, MA 02492, USA
    Ann N Y Acad Sci 1054:492-4. 2005
    ..Initial clinical studies have shown deferitrin to be well absorbed. Further clinical studies are ongoing to determine the efficiency and safety of deferitrin...
  32. ncbi Colesevelam hydrochloride does not cause maternal or fetal toxicity in rats and rabbits
    Judith K Marquis
    Genzyme Drug Discovery and Development, 153 Second Avenue, Waltham, MA 05451, USA
    Reprod Toxicol 21:197-207. 2006
    ..Colesevelam does not produce developmental toxicity in rats or rabbits, nor does it exhibit pre- or postnatal toxicity in rats at the tested doses...
  33. ncbi Development and evaluation of an isotope dilution LC/MS method for the determination of total homocysteine in human plasma
    Bryant C Nelson
    Genzyme Corporation, Framingham, MA 01701, USA
    Anal Chem 75:775-84. 2003
    ..LC/MS performed well in relation to the other homocysteine methods in terms of its capability to accurately quantify plasma homocysteine over the normal range (5-15 micromol/L)...
  34. ncbi The identification of clinically relevant markers and therapeutic targets
    Charles A Nicolette
    Genzyme Molecular Oncology, Genzyme Corporation 5 Mountain Rd, Framingham MA 01701, USA
    Drug Discov Today 8:31-8. 2003
    ....
  35. ncbi Demonstration of feasibility of in vivo gene therapy for Gaucher disease using a chemically induced mouse model
    John Marshall
    Genzyme Corporation, Framingham, Massachusetts, 01701 9322, USA
    Mol Ther 6:179-89. 2002
    ..Together, these data demonstrate the potential for use of in vivo gene therapy vectors for treating Gaucher disease...
  36. ncbi Phosphatonins: a new class of phosphate-regulating proteins
    Susan C Schiavi
    Applied Genomics, Genzyme Corporation, One Mountain Road, Framingham, Massachusetts 01701, USA
    Curr Opin Nephrol Hypertens 11:423-30. 2002
    ..The molecular characterization of these substances will prove to be critical for understanding phosphate physiology and clinical disorders of phosphate metabolism...
  37. ncbi Fabrazyme--recombinant protein treatment for Fabry's disease
    Debra Barngrover
    Therapeutics Operations Management, Framingham, MA 01701 9322, USA
    J Biotechnol 95:280-2. 2002
  38. ncbi High and sustained transgene expression in vivo from plasmid vectors containing a hybrid ubiquitin promoter
    N S Yew
    Genzyme Corporation, 31 New York Avenue, Framingham, MA 01701 9322, USA
    Mol Ther 4:75-82. 2001
    ..Our results indicate that CpG-reduced plasmid vectors containing a CMV-Ub hybrid promoter may provide the long-term expression required for a practical gene therapeutic...
  39. ncbi Scaleable chromatographic purification process for recombinant adeno-associated virus (rAAV)
    C R O'Riordan
    Genzyme Corporation, Framingham, MA 01701 9322, USA
    J Gene Med 2:444-54. 2000
    ..To address the issue of purification we have developed a process scale method for the rapid and efficient purification of recombinant AAV (rAAV) from crude cellular lysates...
  40. ncbi Renal fibrosis in mice treated with human recombinant transforming growth factor-beta2
    S Ledbetter
    Genzyme Corporation, Framingham, Massachusetts 01701, USA
    Kidney Int 58:2367-76. 2000
    ..We studied the effects of administering human recombinant TGF-beta2 to adult mice...
  41. ncbi The role of CpG motifs in immunostimulation and gene therapy
    R K Scheule
    Gene Transfer Research, Genzyme Corporation, 31 New York Avenue, Framingham, MA 01701 9322, USA
    Adv Drug Deliv Rev 44:119-34. 2000
    ....
  42. ncbi Inhibitory effect of cystic fibrosis sputum on adenovirus-mediated gene transfer in cultured epithelial cells
    M A Perricone
    Genzyme, Framingham, MA 01701, USA
    Hum Gene Ther 11:1997-2008. 2000
    ..We conclude that preexisting adenovirus-specific antibodies present in some of the patient samples were the predominant factor inhibiting Ad-mediated gene transfer...
  43. ncbi Immunogene therapy for murine melanoma using recombinant adenoviral vectors expressing melanoma-associated antigens
    M A Perricone
    Genzyme Molecular Oncology, Framingham, Massachusetts 01701 9322, USA
    Mol Ther 1:275-84. 2000
    ..These observations provide insights into the clinical applicability of adenoviral vaccines for immunotherapy of malignant diseases...
  44. ncbi Recombinant human thyroid-stimulating hormone (rhTSH): clinical development
    C Incerti
    Medical, Clinical and Regulatory Affairs, Genzyme Europe, Naarden, The Netherlands
    J Endocrinol Invest 22:8-16. 1999
    ..These safety and efficacy findings have led to regulatory approval of rhTSH for diagnostic use in the United States in December 1998; regulatory approval is pending in the European Union...
  45. ncbi Increased duration of transgene expression in the lung with plasmid DNA vectors harboring adenovirus E4 open reading frame 3
    N S Yew
    Genzyme Corporation, Framingham, MA 01701 9322, USA
    Hum Gene Ther 10:1833-43. 1999
    ....
  46. ncbi Joint models for efficient estimation in proportional hazards regression models
    Peter Slasor
    Genzyme Corporation, One Kendall Square, Cambridge, MA 02139 1562, USA
    Stat Med 22:2137-48. 2003
    ..In a simulation, the estimated efficiency gain over the standard proportional hazards model is 6.4 per cent. In clinical trial data, the estimated efficiency gain over the standard proportional hazards model is 10.2 per cent...
  47. ncbi Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients
    Steven K Burke
    Genzyme Corporation, 153 Second Avenue, Waltham, MA 02451, USA
    Adv Ren Replace Ther 10:133-45. 2003
    ..This meta-analysis suggests that sevelamer offers a dual therapeutic benefit in dialysis patients-a population at high risk for cardiovascular disease-by improving phosphorus control and the lipid profile, without altering serum calcium...
  48. ncbi Hydrodynamic delivery of DNA
    Bradley L Hodges
    Genzyme Corporation, 31 New York Avenue, Framingham, MA 01701, USA
    Expert Opin Biol Ther 3:911-8. 2003
    ..A review of the mechanisms for transfecting hepatocytes, as well as potential uses of this approach in various research and clinical applications, will also be discussed...
  49. ncbi Marine-derived cancer therapeutics making a splash
    Timothy K Maclachlan
    Division of Pharmocology Toxicology, Genzyme Corporation, Framingham, Massachusetts 01701, USA
    Cancer Biol Ther 4:883-4. 2005
  50. ncbi Dietary administration of colesevelam hydrochloride does not affect fertility or reproductive performance in rats
    Judith K Marquis
    Genzyme Drug Discovery and Development, Waltham, Massachusetts 02451, USA
    Int J Toxicol 23:357-67. 2004
    ..Based on these data, colesevelam HCl does not have any significant adverse reproductive or fertility effects in rats, even when administered at doses approximately 30 times greater than the approved clinical dose...
  51. ncbi Controlling the kinetics of transgene expression by plasmid design
    Nelson S Yew
    Genzyme Corporation, 31 New York Avenue, Framingham, MA 01701 9322, USA
    Adv Drug Deliv Rev 57:769-80. 2005
    ..Vectors can also be designed to respond to the local environment of a given cell or tissue, or engineered to respond to a small molecule drug...
  52. ncbi The distribution, metabolism, and elimination of clofarabine in rats
    Peter L Bonate
    Genzyme Oncology, San Antonio, TX 78229, USA
    Drug Metab Dispos 33:739-48. 2005
    ..In rat, dog, and human hepatocytes, 95, 96, and 99.8% [14C]clofarabine remained, respectively, after 6 h of incubation. Eleven metabolites were observed, with the largest constituting 2.5% of the radioactivity...
  53. ncbi Intracerebral transplantation of adult mouse neural progenitor cells into the Niemann-Pick-A mouse leads to a marked decrease in lysosomal storage pathology
    L S Shihabuddin
    Genzyme Corporation, Framingham, Massachusetts 01701, USA
    J Neurosci 24:10642-51. 2004
    ..Potentially, NPCs may serve as a useful gene transfer vehicle for the treatment of CNS pathology in other lysosomal storage diseases and neurodegenerative disorders...
  54. ncbi N-linked oligosaccharide analysis of glycoprotein bands from isoelectric focusing gels
    Qun Zhou
    Therapeutic Protein Research, Genzyme Corporation, P O Box 9322, Framingham, MA 01701, USA
    Anal Biochem 335:10-6. 2004
    ..The sialic acid content of these bands correlated with that predicted from the corresponding oligosaccharide analyses...
  55. ncbi Mitotic and meiotic instability of a telomere association involving the Y chromosome
    Bing Huang
    Genzyme Genetics, Orange, California 92868, USA
    Am J Med Genet A 129:120-3. 2004
    ..The interstitial telomere sequences at the junction of the telomere association may explain the mitotic and meiotic instability of the association...
  56. pmc Vascular gene expression in nonneoplastic and malignant brain
    Stephen L Madden
    Genetics and Genomics, 5 Mountain Rd, Framingham, MA 01701, USA
    Am J Pathol 165:601-8. 2004
    ..Additional characterization of this extensive brain endothelial cell gene expression database will provide unique molecular insights into vascular gene expression...
  57. ncbi Noradrenergic regulation of prolactin secretion at the level of the paraventricular nucleus of the hypothalamus: functional significance of the alpha-1b and beta-adrenergic receptor subtypes
    James C Dodge
    Behavioral Neuroscience Program, Psychology Department, SUNY at Buffalo, USA
    Brain Res 1016:240-6. 2004
    ..The results of this study indicate that both the alpha-1b and beta-adrenergic receptor subtypes have a significant role in regulating circulating levels of prolactin at the level of the PVN in the Siberian hamster...
  58. ncbi Monitoring the 3-year efficacy of enzyme replacement therapy in fabry disease by repeated skin biopsies
    Beth L Thurberg
    Department of Pathology, Genzyme Corporation, Cambridge, Massachusetts 01701 9322, USA
    J Invest Dermatol 122:900-8. 2004
    ....
  59. ncbi A modified model of graft-versus-host-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease
    Melanie C Ruzek
    Genzyme Corporation, Framingham, Massachusetts 01701, USA
    Arthritis Rheum 50:1319-31. 2004
    ..The present studies were undertaken to determine if alteration of the induction of GVH-induced scleroderma could result in a model that more fully represented the human condition...
  60. ncbi Correction of sequence-based artifacts in serial analysis of gene expression
    Viatcheslav R Akmaev
    Genzyme Corporation, Framingham, MA 01701 9322, USA
    Bioinformatics 20:1254-63. 2004
    ..By virtue of their low-random incidence, such tag errors have minimal impact on differential expression analysis. However, to fully exploit the value of large SAGE tag datasets, it is desirable to account for and correct tag artifacts...
  61. ncbi The phosphatonin pathway: new insights in phosphate homeostasis
    Susan C Schiavi
    Genzyme Corporation, Framingham, Massachusetts 01701 9322, USA
    Kidney Int 65:1-14. 2004
    ..Future experiments should clarify their physiologic and pathologic roles in phosphate metabolism...
  62. ncbi Active site titration of the tyrosine phosphatases SHP-1 and PTP1B using aromatic disulfides. Reaction with the essential cysteine residue in the active site
    M J Pregel
    Pharmaceutical Biotechnology Sector, Biotechnology Research Institute, National Research Council of Canada, Montreal, Quebec H4P 2R2, Canada
    J Biol Chem 272:23552-8. 1997
    ..0. These findings demonstrate the utility of aromatic disulfides as active site titrants and reactivity probes for tyrosine phosphatases...